Page 354 - Read Online

Smigiel et al. J Cancer Metastasis Treat 2019;5:47 I http://dx.doi.org/10.20517/2394-4722.2019.26 Page 19 of 20

chemoresistance in triple negative breast cancer. Nat Commun 2018;9:2897.
216. Hui M, Cazet A, Nair R, Watkins DN, O'Toole SA, et al. The Hedgehog signalling pathway in breast development, carcinogenesis and
cancer therapy. Breast Cancer Res 2013;15:203.
217. O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, et al. Hedgehog overexpression is associated with stromal interactions and
predicts for poor outcome in breast cancer. Cancer Res 2011;71:4002-14.
218. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013;19:1410-22.
219. Chuang PT, Kawcak T, McMahon AP. Feedback control of mammalian Hedgehog signaling by the Hedgehog-binding protein, Hip1,
modulates Fgf signaling during branching morphogenesis of the lung. Genes Dev 2003;17:342-7.
220. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
221. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22.
222. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Clin Cancer Res 2002;8:945-54.
223. Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, et al. Identification of novel small molecules that inhibit STAT3-dependent
transcription and function. PLoS One 2017;12:e0178844.
224. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality
in therapy-resistant chronic myeloid leukemia. Leukemia 2015;29:586-97.
225. Liu F, Cao J, Wu J, Sullivan K, Shen J, et al. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J
Invest Dermatol 2013;133:2041-9.
226. Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved
in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010;28:1930-9.
227. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability
of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009;106:268-73.
228. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven
pancreatic cell plasticity and cancer. Cancer Cell 2013;23:406-20.
229. Baselga J, Im S-A, Iwata H, Cortés J, De Laurentiis M, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal,
hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase
3 trial. Lancet Oncol 2017;18:904-16.
230. Anderson EJ, Mollon L, Dean JL, Aguilar A, Davis LE, et al. A systematic literature review of the clinical prognosis of HR+/HER2-
advanced or metastatic breast cancer with and without PIK3CA mutation. J Clin Oncol 2018;36.
231. Baselga J, Dent SF, Cortés J, Im Y-H, Diéras V, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients
(pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary
analysis from SANDPIPER. J Clinl Oncol 2018;36:LBA1006.
232. Sharma P, Abramson VG, O'Dea A, Lewis S, Scott JN, et al. Abstract P6-11-08: Safety and efficacy results from phase I study of BYL
719 plus nab-paclitaxel in HER 2 negative metastatic breast cancer. Cancer Res 2017;77:P6-11-08.
233. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is
required for viability and maintenance. Proc Natl Acad Sci U S A 2007;104:16158-63.
234. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009;18:17-25.
235. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human
colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
236. Chang WW, Lin RJ, Yu J, Chang WY, Fu CH, et al. The expression and significance of insulin-like growth factor-1 receptor and its
pathway on breast cancer stem/progenitors. Breast Cancer Res 2013;15:R39.
237. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-
resistant non-small cell lung cancer cells. Oncogene 2013;32:209-21.
238. Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in
HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat 2012;136:717-27.
239. Ekyalongo RC, Yee D. Revisiting the IGF-1R as a breast cancer target. NPJ Precis Oncol 2017;1.
240. Liu Y, Zhang X, Liu J, Hou G, Zhang S, et al. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem
cells via PI3K/mTOR pathway: an experimental study. Tumour Biol 2014;35:1275-86.
241. Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on
human breast cancer stem cells in vitro and in vivo. Tumour Biol 2012;33:1349-62.
242. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts
involving multiple cancer cell types. Cancer Res 2011;71:3196-201.
243. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. Identification of selective inhibitors of cancer stem cells by high-throughput
screening. Cell 2009;138:645-59.
244. Kumar D, Shankar S, Srivastava RK. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular
mechanisms. Mol Cancer 2013;12:171.
245. Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, et al. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem
cells. Cancer Res 2015;75:446-55.
246. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast
cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
247. D'Angelo RC, Ouzounova M, Davis A, Choi D, Tchuenkam SM, et al. Notch reporter activity in breast cancer cell lines identifies a